glp-1 ibs and Gut Health: Addressing Metabolic Dysfunction for Physicians GLP-1 Series | Part 4

[9] In clinical studies, liraglutide consistently lowers fasting and after-meal glucose levels and improves long-term blood sugar control

People on tirzepatide lost about 50 pounds originally and gained an average ten pounds back after switching to orforglipron

The medication is not recommended for long-term use, generally limited to a maximum of 12 weeks

As NAD+ levels decline with age, obesity, and metabolic disease, sirtuin function diminishes, contributing to insulin resistance, mitochondrial dysfunction, and fat accumulation

Accordingly, for all the outcomes, the certainty of evidence was deemed low-tovery low in the GRADE analysis

Why Eating Less Doesnt Always Mean Getting Enough Nutrients The research on GLP-1 medications is clear on one thing: people are eating less, but they are not necessarily eating better